Giant Biogene Holding Co., Ltd. (Giant Biogene) will seek shareholder approval at its Annual General Meeting (AGM) on 28 May 2026 for several key resolutions, including a change of external auditor, sizeable cash dividends and refreshed share mandates.
Key AGM Proposals 1. Auditor Replacement: • Ernst & Young, auditor for the past seven financial years, will retire. • KPMG is nominated as successor, with an estimated audit fee capped at RMB2.20 million.
2. Cash Distribution: • Final dividend: RMB0.5390 per share. • Special dividend: RMB0.6714 per share. • Record date: 8 June 2026; expected payment date: on or about 25 June 2026.
3. Share Mandates: • Repurchase mandate—up to 10% of issued shares (maximum 106.17 million shares based on the current 1.06 billion share base). • Issuance mandate—up to 20% of issued shares (maximum 212.34 million shares), extendable by shares repurchased under the above mandate.
4. Board Matters: • Re-election of executive directors Ms. Fang Juan, Ms. Zhang Huijuan and Ms. Yan Yubo.
Dividend Logistics and Book Closure • Share register closure for AGM voting: 22–28 May 2026. • Share register closure for dividend entitlement: 3–8 June 2026.
Capital Structure Snapshot • Issued share capital: 1.06 billion shares. • Mandated repurchases and issuances would not trigger a mandatory offer under the Hong Kong Takeovers Code or reduce the public float below regulatory thresholds, according to the board.
The board recommends shareholders vote in favour of all resolutions, citing enhanced corporate governance, continued capital-return flexibility and a stable payout. The AGM will be held at the company’s headquarters in Xi’an, Shaanxi Province.
Comments